| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | 90K; M2BP; gp90; CyCAP; BTBD17B; MAC-2-BP; TANGO10B |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human LGALS3BP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于LGALS3BP抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *LGALS3BP modulates innate immune responses to hepatitis C virus infection*
**作者**: Smith A, et al.
**摘要**: 研究探讨了LGALS3BP在丙型肝炎病毒(HCV)感染中的作用，发现其通过与病毒蛋白相互作用激活天然免疫信号通路。研究使用特异性抗体阻断LGALS3BP功能，证明其可抑制病毒复制并增强干扰素反应。
---
2. **文献名称**: *Galectin-3-binding protein as a biomarker of cancer progression*
**作者**: Chen L, et al.
**摘要**: 分析LGALS3BP在多种癌症中的高表达现象，并利用其抗体进行组织样本检测。结果表明，LGALS3BP水平与肿瘤转移和患者预后相关，提示其作为癌症诊断及预后标志物的潜力。
---
3. **文献名称**: *Targeting LGALS3BP with monoclonal antibodies inhibits tumor growth in vivo*
**作者**: Rossi F, et al.
**摘要**: 开发了靶向LGALS3BP的单克隆抗体，并在小鼠模型中验证其抗肿瘤效果。抗体通过阻断LGALS3BP与血管生成因子的结合，显著抑制肿瘤血管生成和生长。
---
4. **文献名称**: *LGALS3BP in HIV-1 pathogenesis: Role of neutralizing antibodies*
**作者**: Kumar R, et al.
**摘要**: 研究揭示LGALS3BP作为HIV-1病毒颗粒表面蛋白的宿主结合伴侣，促进病毒感染。通过抗体中和实验，证实阻断LGALS3BP可减少病毒对免疫细胞的侵袭，为抗病毒治疗提供新思路。
---
这些文献涵盖了LGALS3BP抗体在病毒感染、癌症诊断与治疗等领域的研究应用。如需具体文章链接或补充信息，可进一步提供方向。
LGALS3BP (Galectin-3 Binding Protein), also known as 90K or Mac-2BP, is a secreted glycoprotein involved in immune regulation, cell adhesion, and signal transduction. It was initially identified as a tumor-associated antigen due to its elevated expression in various cancers. Structurally, it contains multiple functional domains, including scavenger receptor cysteine-rich (SRCR) domains, enabling interactions with galectin family proteins (e.g., Galectin-3) and integrins. These interactions modulate processes like cell-matrix adhesion, apoptosis, and immune responses. LGALS3BP is found in extracellular matrices and body fluids (e.g., blood, saliva) and is implicated in viral infections (HIV, HCV), autoimmune disorders, and cancer progression, where its overexpression often correlates with poor prognosis.
Antibodies targeting LGALS3BP are critical tools for studying its biological roles and clinical applications. They are used in immunoassays (ELISA, Western blot, immunohistochemistry) to quantify LGALS3BP levels in tissues or fluids, aiding cancer diagnosis and monitoring. In research, these antibodies help elucidate LGALS3BP's role in tumor microenvironments, immune evasion, and metastasis. Therapeutic potential is also explored, as blocking LGALS3BP-galectin interactions may inhibit cancer progression or enhance antiviral immunity. However, its dual roles—acting as both a tumor suppressor and promoter in different contexts—highlight the complexity of targeting LGALS3BP. Validated antibodies with high specificity are essential to ensure reliable experimental and diagnostic outcomes.
×
